Enterprise Value

27.51M

Cash

13.33M

Avg Qtr Burn

-5.00M

Short % of Float

0.66%

Insider Ownership

1.93%

Institutional Own.

8.00%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
XACIATO (DARE-BV1) Details
Bacterial infection

Approved

Quarterly sales

Sildenafil Cream, 3.6% Details
Sexual dysfunction, Sexual desire disorder

Phase 3

Initiation

Ovaprene® Details
Contraceptive

Phase 3

Initiation

DARE-PDM1 Details
Primary dysmenorrhea

Phase 1

Data readout

IND

Submission

IND

Submission